Febrile neutropenia risk assessment tool: Improving clinical outcomes for oncology patients

O’Brien, Catherine; Dempsey, Orla; Kennedy, M. J.

doi:10.1016/j.ejon.2013.11.002

Cited by 7 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The authors of the current article believe that health care is now entrenched in the era of the shared decision-making model of practice, where patients are being asked or expected to participate in the cancer treatment decision-making process (Charles et al, 1999;Colella & DeLuca, 2004;Elwyn et al, 2012;Fenton, 2003;Kane, Halpern, Squiers, Treiman, & Mc-Cormack, 2014;Muller, 2012). The paternalistic model of care has faded in popularity (Feldmann, 1973;McKinstry, 1992;Medhat et al, 1988) and the shared decision-making model of care is taking hold, particularly in the cancer care setting (Lund, Jonler, Graversen, Borre, & Bro, 2013;Shad, Myers, & Hennessy, 2012;Tariman, Berry, Cochrane, Doorenbos, & Schepp, 2010).…”

Section: Discussionmentioning

confidence: 99%

“…The nurse is the most trusted healthcare team member according to a Gallup survey (Newport, 2012). For this reason, nurses are in an excellent position to advocate for the patient's right to autonomy and informed decision making.…”

Section: Advocacymentioning

confidence: 99%

“…Nurses have been involved in outcome evaluation initiatives because of popularity of evidence-based practice. One study demonstrated that nurses were able to develop, implement, and evaluate the effectiveness of a nurse-led risk assessment tool for the reduction of febrile neutropenia in hospitalized patients with cancer receiving chemotherapy (O'Brien, Dempsey, & Kennedy, 2014). Advanced practice nurses are also involved in outcome evaluation to examine the efficacy and cost-benefit analysis of undertreating the side effects of chemotherapy, such as nausea and vomiting (Viale, Grande, & Moore, 2012).…”

Section: Outcome Evaluationmentioning

confidence: 99%

See 2 more Smart Citations

The Evolving Role of the Nurse During the Cancer Treatment Decision-Making Process: A Literature Review

Tariman¹,

Szubski²

2015

CJON

View full text Add to dashboard Cite

Because of external forces, such as rising cost of health care, increasing healthcare consumerism, and increased emphasis on patient-centered care, the shared model of care is taking hold, particularly in the cancer setting. The evolution of these models has caused a shift in the dialogue related to cancer treatment decision making between patients and physicians, as well as oncology nurses. These events contribute to the evolving role of the nurse during the cancer treatment decision-making process.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Advocacymentioning

confidence: 99%

Section: Outcome Evaluationmentioning

confidence: 99%

See 1 more Smart Citation

The Evolving Role of the Nurse During the Cancer Treatment Decision-Making Process: A Literature Review

Tariman¹,

Szubski²

2015

CJON

View full text Add to dashboard Cite

show abstract

“…Introduction of FN risk assessment tools at individual centers has been shown to reduce the incidence of FN and increase chemotherapy delivery [34,35]. Moreover, studies suggest that standardized risk assessment and use of G-CSF PP are feasible in routine practice and can greatly improve FN outcomes in patients undergoing chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia

et al. 2015

View full text Add to dashboard Cite

Febrile neutropenia (FN) is a potentially fatal complication of chemotherapy. This prospective, observational study describes physicians' approaches toward assessing FN risk in patients receiving chemotherapy regimens with an intermediate (10-20 %) FN risk. In the baseline investigator assessment, physicians selected factors considered important when assessing overall FN risk and deciding on granulocyte colony-stimulating factor (G-CSF) primary prophylaxis (PP). Physicians then completed patient assessments using the same lists of factors. The final FN risk scores and whether G-CSF PP was planned were reported. The final analysis included 165 physicians and 944 patients. The most frequently considered factor in both assessments was chemotherapy agents in the backbone (88 % of investigator and 93 % of patient assessments). History of FN (83 %), baseline laboratory values (76 %) and age (73 %) were commonly selected at baseline, whereas tumor type (72 %), guidelines (62 %) and tumor stage (43 %) were selected most during patient assessments. Median investigator-reported FN risk threshold for G-CSF PP was 20 % (range 10-85 %). G-CSF PP was planned in 82 % of patients with an FN risk at or above this threshold; therefore, almost one-fifth of qualifying patients would not receive G-CSF PP. Physicians generally follow guidelines, but also consider individual patient characteristics when assessing FN risk and deciding on G-CSF PP. A standardized FN risk assessment may optimize the use of G-CSF PP, which may minimize the incidence of FN in patients undergoing chemotherapy with an intermediate FN risk. ClinicalTrials.gov Identifier: NCT01813721.

show abstract

“…Thus, most of them were treatment- rather than prevention-oriented [ 14 - 15 ] . So a nursing work-based and prevention-oriented tool for oncology children is needed [ 16 ] . Due to historical, political, social and economical conditions, health systems differ among countries.…”

Section: Introductionmentioning

confidence: 99%

Developing a tool for nurses to assess risk of infection in pediatric oncology patients in China: a modified Delphi study

Zhou¹,

Cui²,

Wang³

et al. 2016

J Biomed Res

View full text Add to dashboard Cite

Infections are identified as the most common preventable cause of death in pediatric oncology patients. Assessing and stratifying risk of infections are essential to prevent infection in these patients. To date, no tool can fulfill this demand in China. This study aimed to develop a nursing work-based and Chinese-specific tool for pediatric nurses to assess risk of infection in oncology patients. This research was a modified Delphi study. Based on a literature review, a 37-item questionnaire rating on a 0–5 scale was developed. Twenty-four experts from 8 hospitals in 6 provinces of China were consulted for three rounds. Consensus for each item in the first round was defined as: the rating mean was > 3 and the coefficient of variation (CV) was < 0.5. Consensus for each item in the second round was defined as CV < 0.3. Consensus among experts was defined as: P value of Kendall's coefficient of concordance (W) < 0.05. After three rounds of consultation, a two-part tool was developed: the Immune Status Scale (ISS) and the Checklist of Risk Factors of Infection (CRFI). There were 5 items in the ISS and 14 in the CRFI. Based on the ISS score, nurses could stratify children into the low-risk and high-risk groups. For high-risk children, nurses should screen risk factors of infection every day by the CRFI, and twice weekly for low-risk children. Further study is needed to verify this tool's efficacy.

show abstract

Febrile neutropenia risk assessment tool: Improving clinical outcomes for oncology patients

Cited by 7 publications

References 36 publications

The Evolving Role of the Nurse During the Cancer Treatment Decision-Making Process: A Literature Review

The Evolving Role of the Nurse During the Cancer Treatment Decision-Making Process: A Literature Review

Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia

Developing a tool for nurses to assess risk of infection in pediatric oncology patients in China: a modified Delphi study

Contact Info

Product

Resources

About